Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Report Date: March 31, 2025
Subject: Announcement of financial results for the three months and year ended December 31, 2024.
Business Overview: Omeros Corporation is a biopharmaceutical company incorporated in Washington, with principal executive offices in Seattle, WA. The company's common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This filing serves as a notification that a press release containing these details (Exhibit 99.1) has been issued, but the financial data itself is not embedded in the text of the 8-K.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data to compare current performance against prior comparable periods. It only references the issuance of results for the periods ended December 31, 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook: No specific guidance, outlook, or management commentary is included in the text of this Form 8-K. Such information is contained within the referenced press release (Exhibit 99.1).
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information in this report and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to liability under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933. It further states that the information shall not be incorporated by reference into any other SEC filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2025) for actual financial figures regarding revenue, net income, and cash position for the three months and year ended December 31, 2024.
- Verify the company's liquidity position and debt obligations as detailed in the full press release, as these are not listed in the 8-K summary text.
- Check for any forward-looking statements or updated clinical trial timelines in the referenced press release.
- Confirm the trading status of OMER on The Nasdaq Stock Market LLC.